Article Sidebar
Published:
Jun 22, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Wogonoside exerts potential anti-tumor activity against bladder cancer <i>in vivo</i> and <i>in vitro</i> via regulation of GSK3β/ERK/AKT signaling pathway
Abstract
Purpose: To explore the antitumor activity of wogonoside on bladder cancer, and its underlying mechanism of action.
Methods: Methyl thiazolyl tetrazolium (MTT) assay was applied to evaluate the anti-proliferative activity of wogonoside (2 - 128 μM) against bladder cancer 5637 cell line at different times, and the half maximal inhibitory concentration (IC50) was measured. The antitumor activity of wogonoside (30 mg/kg, i.p.) against bladder cancer 5637 cell line was confirmed via in vivo experiments on nude mice bearing human bladder cancer 5637 cells. Additionally, western blotting assay and enzyme-linked immunosorbent assay (ELISA) were used to investigate expression levels of caspase-3, caspase-9, B cell lymphoma/leukemia-2 (Bcl-2), Bcl-2 associated X protein (Bax), phosphorylated (p)-glycogen synthase kinase (GSK)-3β, p-extracellular signal-regulated kinases (p-ERK), and p-(protein kinase B) AKT.
Results: The in vitro results reveal that wogonoside has remarkable anti-proliferative activity against bladder cancer 5637 cells with IC50 of 20.59 μM, in a concentration-and time-dependent manner. Furthermore, wogonoside treatment also suppressed tumor volume of nude mice bearing bladder cancer 5637 cell (p < 0.01). The potential mechanisms seems to be mainly associated with apoptosis mediated by mitochondria via up-regulation of caspase-3, caspase-9, and Bax levels, and downregulation of Bcl-2, p-GSK-3β, p-ERK, and p-AKT.
Conclusion: The results reveal that wogonoside possesses anti-tumor potentials against bladder cancer. Further translational studies are warranted to test the clinical application of this medicinal agent in bladder cancer.
